London · Delayed Price · Currency is GBP · Price in GBX Spire Healthcare Group Earnings Call Transcripts
Fiscal Year 2025
-
Revenue grew 4.5% with strong private and primary care momentum, while NHS volumes slowed due to budget constraints. Adjusted EBITDA rose 3.2% and free cash flow surged 65%, supported by £30m in transformation savings. NHS uncertainty remains a key risk for 2026.
-
H1 results met guidance with 4.9% revenue growth and 2.8% higher adjusted EBITDA, driven by efficiency savings and strategic transformation. NHS and primary care segments showed strong growth, while private volumes faced headwinds. Full-year outlook remains in line with expectations.
-
Primary care is a major growth focus, targeting £40 million EBITDA through organic expansion, new services, and M&A, with strong NHS contract visibility and a CapEx-light model. Service integration, digital delivery, and a data-driven approach underpin operational efficiency and market reach.
Fiscal Year 2024
-
Full-year 2024 results showed strong revenue and margin growth, with adjusted EBITDA up 9% and all core metrics meeting guidance. Efficiency programs are ahead of plan, offsetting significant cost pressures, and the outlook remains positive for mid-single-digit growth in 2025.
-
Strong H1 2024 results with revenue up 12.7% and adjusted EBITDA up 10.8%, driven by PMI and NHS growth, margin expansion, and successful integration of Vita. Cost savings and efficiency programs are on track, supporting unchanged full-year guidance and positive medium-term outlook.